| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8114885 | NOVARTIS | Chemical compounds |
Dec, 2021
(2 years ago) | |
| US7262203 | NOVARTIS | Pyrimidineamines as angiogenesis modulators |
Dec, 2021
(2 years ago) | |
| US7105530 | NOVARTIS | Pyrimidineamines as angiogenesis modulators |
Oct, 2023
(6 months ago) | |
Votrient is owned by Novartis.
Votrient contains Pazopanib Hydrochloride.
Votrient has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Votrient are:
- US8114885
- US7262203
- US7105530
Votrient was authorised for market use on 19 October, 2009.
Votrient is available in tablet;oral dosage forms.
Drug patent challenges can be filed against Votrient from 19 October, 2013.
The generics of Votrient are possible to be released after 19 October, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-23) | Apr 26, 2019 |
| New Chemical Entity Exclusivity(NCE) | Oct 19, 2014 |
| New Indication(I-649) | Apr 26, 2015 |
| Orphan Drug Exclusivity(ODE) | Apr 26, 2019 |
Drugs and Companies using PAZOPANIB HYDROCHLORIDE ingredient
NCE-1 date: 19 October, 2013
Market Authorisation Date: 19 October, 2009
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
VOTRIENT family patents
